PEMF for Shoulder
Inflammation.

July 2026 · 9 min read · Clinical Protocol

What Is Shoulder Inflammation?

Shoulder inflammation is an umbrella term covering three frequently co-occurring conditions: subacromial bursitis (inflammation of the bursa between the rotator cuff and the acromion), rotator cuff tendinitis (primarily supraspinatus tendinopathy), and shoulder periarthritis (diffuse peri-articular inflammation). Together, these constitute 40–60% of all shoulder pain presentations in clinical practice and are the most common reason patients present to physiotherapy, orthopedic, and sports medicine clinics.

The subacromial space — a narrow corridor approximately 6–14 mm wide — houses the supraspinatus tendon, the long head of the biceps, and the subacromial bursa. Repetitive overhead activity, trauma, postural imbalance, or degeneration narrows this space, triggering a cascade of inflammatory signaling that standard care — NSAIDs, corticosteroid injections, and rest — addresses only transiently.

The Evidence Base: Landmark and Modern Studies

The foundational PEMF study for shoulder inflammation is Binder & Hazleman (1985, BMJ), a double-blind, placebo-controlled RCT in 29 patients with refractory rotator cuff tendinitis. Results: 73% improvement in the PEMF group vs. 42% in the placebo group — a clinically and statistically significant difference that formed a core part of the FDA 510(k) clearance dossier.

Modern evidence from PMC12088032 (shoulder PEMF meta-analysis, 9 RCTs) documents:

• VAS pain reduction: −2.6 cm (mean)
• DASH (Disabilities of the Arm, Shoulder, and Hand) score: 45.2 → 21.8 (51.8% improvement)
• Functional outcome SMD: 1.14 (large effect)

PMC12916110 (Frontiers in Sports Medicine, 2026 systematic review, 4 RCTs, n=243 soft-tissue shoulder conditions) confirmed these effects with a dose-response relationship: ≥10 sessions at 8–75 Hz produced superior outcomes to fewer sessions or lower frequencies.

The multicenter RCT anchor PMC11914662 (n=91, 5 orthopedic clinics) provides the strongest recent data: 36% pain reduction vs. 10% standard care and 55% medication reduction — findings applicable to the shoulder inflammation patient population. This is the same evidence base that underpins the 70+ PainFree clinics operating across Israel (population: 9M) — now expanding to the Philippines.

Why Standard Care Falls Short

• NSAIDs reduce prostaglandin synthesis systemically but do not reach the subacromial bursa in therapeutic concentrations — and carry GI, renal, and cardiovascular risks with long-term use.
• Corticosteroid injections reduce inflammation acutely but accelerate tendon degeneration with repeated use; 3+ injections are associated with 2.8× increased rotator cuff tear risk (Zhaeentan et al., 2021, JBJS).
• Rest allows acute inflammation to subside but does not address the underlying tissue hypoxia, fibrosis, or biomechanical imbalance that drives recurrence.
• Physiotherapy alone improves function but has limited effect on the biochemical inflammatory milieu of the subacromial space.

Four Mechanisms of PEMF Action in Shoulder Inflammation

1. NF-κB pathway suppression — PEMF inhibits nuclear factor-kappa B, reducing transcription of IL-1β, IL-6, TNF-α, and COX-2. This anti-inflammatory effect is pharmacologically similar to NSAIDs but without systemic distribution.
2. Adenosine A2A receptor activation — upregulates intracellular cAMP, triggering anti-inflammatory macrophage polarization (M1 → M2 shift) within the inflamed bursa and peritendinous tissue.
3. Improved subacromial microcirculation — PEMF-induced eNOS upregulation increases nitric oxide, dilating peritendinous capillaries and improving oxygen delivery to the relatively avascular supraspinatus tendon (critical zone: 1 cm proximal to insertion).
4. Fibroblast activation and type I collagen synthesis — at 50–75 Hz, PEMF stimulates tenocyte proliferation and collagen remodeling, addressing the underlying tendinopathy (degenerative change within the tendon matrix) that predisposes to recurrence.

Subacromial Bursitis: Specific Considerations

Subacromial bursitis presents with a classic painful arc (60–120° abduction), night pain, and tenderness at the anterior acromion. The bursa itself — a fluid-filled sac with no intrinsic blood supply — responds poorly to systemic anti-inflammatory medications. PEMF's direct tissue penetration of 20–25 cm ensures the electromagnetic field reaches the subacromial bursa and peritendinous tissue regardless of overlying adipose or muscle depth.

The Hawkins-Kennedy test (sensitivity 72–79%) and Neer's sign (sensitivity 72%) confirm impingement syndrome, while ultrasound confirms bursal thickening (normal: ≤2 mm; bursitis: >2 mm, often 4–8 mm in acute cases).

Clinical Protocol

Contraindications & Precautions

Contraindications are narrow: active cardiac pacemaker, pregnancy (first trimester caution over shoulder/upper thorax), active malignancy in the treatment field, and active epilepsy with poorly controlled seizures. Metal implants (surgical anchors, plates, screws) are generally not a contraindication — titanium and stainless surgical hardware is non-ferromagnetic and PEMF-compatible. A pre-treatment questionnaire covering these four contraindications is sufficient screening.

Precaution note: in acute bursitis with marked swelling, begin with lower intensity (15–20 mT) and 8–15 Hz for the first 2 sessions to avoid a transient inflammatory flare. Titrate upward as tolerated.

PEMF vs. Conventional Shoulder Inflammation Treatments

Philippine Market Context

With 3 million construction workers performing daily overhead work and 1.3 million BPO agents maintaining sustained shoulder tension postures, shoulder inflammation is one of the highest-volume outpatient pain presentations in the Philippines. Corticosteroid injections — the typical next-step after NSAIDs — carry significant long-term risk and limited repeat dosing. PEMF provides the only non-invasive, non-pharmacological mechanism that acts directly on the tissue biology driving the condition.

Philippine PEMF session cost: ₱1,500–₱2,500/session. A full course of 12 sessions (₱18,000–₱30,000) is substantially below the cost of surgical decompression and eliminates the need for repeated injections. Clinic ROI data available in the investor brief.

Who Benefits Most

• Overhead workers (construction, electricians, painters, warehouse staff)
• Athletes (swimming, volleyball, baseball/softball, tennis, badminton)
• BPO workers with chronic shoulder tension and postural dysfunction
• Post-injection failures — patients who had 1–3 corticosteroid injections with inadequate or diminishing benefit
• Pre-surgical candidates — PEMF as a conservative trial before arthroscopic decompression